US FDA’s Potential Class Of 2021 By The Numbers
Our infographic breaks down the bumper crop.
You may also be interested in...
Dermatology, chronic kidney disease and liver disease therapies stand out in a crowd of user fee goals that is actually bigger than at the same point in 2020.
Keeping Track: US FDA Clears Bylvay, Fexinidazole, Gives Retifanlimab CRL; JAK Inhibitor Class Delays
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Pink Sheet reporters and editors discuss increasing complete response letters for breakthrough designees, FDA changing course on statin use during pregnancy, and efforts to use pandemic innovations to improve clinical research going forward.